Reaction

Thrombophlebitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,486 reports · 107 co-occurring drugs

As of the last recalculation, Thrombophlebitis appears in 3,486 FAERS reports alongside 107 co-occurring drug terms. The strongest observed disproportionality signal is ETONOGESTREL AND ETHINYL ESTRADIOL (PRR 24.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Etonogestrel And Ethinyl Estradiol	88	24.3	24.4
Drospirenone And Ethinyl Estradiol	118	16.5	16.5
Dalteparin Sodium	26	14.8	14.8
Iron Sucrose	21	13.2	13.3
Fondaparinux Sodium	16	11.9	11.9
Baricitinib	15	9.3	9.3
Fosaprepitant Dimeglumine	20	8.7	8.7
Quinine	12	8.4	8.4
Promethazine Hydrochloride	23	7.4	7.4
Terbinafine Hydrochloride	11	7.4	7.4
Chlorhexidine Gluconate	11	7.2	7.2
Heparin Sodium	16	7.0	7.0
Thiotepa	11	6.9	6.9
Tranexamic Acid	10	6.7	6.7
Clindamycin Phosphate	37	6.7	6.7
Phenobarbital	16	6.6	6.6
Clindamycin	31	6.6	6.6
Aprepitant	20	6.5	6.5
Carfilzomib	30	6.4	6.4
Midazolam	26	6.2	6.2
Magnesium Sulfate In Water For	13	6.1	6.1
Midazolam Hydrochloride	27	6.0	6.0
Enoxaparin Sodium	57	6.0	6.0
Magnesium Sulfate Heptahydrate	13	6.0	6.0
Magnesium Sulfate	13	6.0	6.0
Cisplatin	75	5.8	5.8
Filgrastim	36	5.8	5.8
Gemcitabine Hydrochloride	50	5.7	5.7
Thalidomide	34	5.6	5.6
Polatuzumab Vedotin	9	5.5	5.5
Testosterone Cypionate	8	5.4	5.4
Exemestane	19	5.3	5.3
Amphotericin B	11	5.3	5.3
Bendamustine Hydrochloride	10	5.0	5.0
Valproate Sodium	17	4.9	4.9
Gemcitabine	32	4.9	4.9
Olanzapine Pamoate	33	4.9	4.9
Rasagiline Mesylate	9	4.8	4.8
Propofol	29	4.8	4.8
Ceftriaxone	25	4.6	4.6
Busulfan	12	4.6	4.6
Fulvestrant	25	4.5	4.5
Cefazolin Sodium	9	4.5	4.5
Levodopa	9	4.5	4.5
Letrozole	45	4.4	4.4
Fluorouracil Cream, 0.5%	55	4.4	4.4
Fluorouracil	55	4.3	4.3
Amantadine	11	4.3	4.3
Ceftriaxone Sodium	27	4.2	4.2
Infliximab-Dyyb	20	4.1	4.1
Anastrozole	25	4.1	4.1
Bleomycin Sulfate	7	4.1	4.1
Granisetron Hydrochloride	7	4.0	4.0
Haloperidol	16	3.9	3.9
Daratumumab	26	3.9	3.9
Haloperidol Lactate	16	3.9	3.9
Etoposide	47	3.9	3.9
Vancomycin	37	3.9	3.9
Panitumumab	10	3.8	3.8
Erythropoietin	13	3.8	3.8
Clobazam	15	3.7	3.7
Doxorubicin	54	3.7	3.7
Metoclopramide	33	3.6	3.6
Micafungin Sodium	5	3.5	3.5
Cyclophosphamide Injection, Solution	102	3.5	3.5
Cyclophosphamide	102	3.5	3.5
Cyclophosphamide For Injection	102	3.5	3.5
Loperamide Hydrochloride Oral	6	3.5	3.5
Bendamustine Hcl	9	3.5	3.5
Lapatinib	9	3.5	3.5
Rivaroxaban	117	3.4	3.4
Darbepoetin Alfa	29	3.2	3.2
Azacitidine	16	3.2	3.2
Lacosamide	20	3.2	3.2
Dexamethasone 1.5 Mg	153	3.2	3.2
Dexamethasone	154	3.2	3.2
Romiplostim	8	3.2	3.2
Paclitaxel	52	3.2	3.2
Paclitaxel (Aibumin-Bound)	43	3.1	3.2
Bevacizumab	63	3.1	3.1
Cortisone Acetate	6	2.9	2.9
Carboplatin	61	2.9	2.9
Capecitabine	44	2.9	2.9
Ifosfamide	10	2.8	2.8
Oxaliplatin	34	2.8	2.8
Doxorubicin Hydrochloride	15	2.8	2.8
Gefitinib	4	2.6	2.6
Pemetrexed Disodium	16	2.5	2.5
Cetuximab	13	2.5	2.5
Bortezomib	35	2.4	2.4
Irinotecan Hydrochloride	5	2.3	2.3
Dabigatran Etexilate	30	2.3	2.3
Azacitidine For	7	2.3	2.3
Obinutuzumab	6	2.2	2.2
Dabigatran Etexilate Mesylate	26	2.1	2.1
Paricalcitol	5	2.1	2.1
Ranibizumab	9	2.0	2.0
Palbociclib	32	2.0	2.0
Guselkumab	12	2.0	2.0
Pegfilgrastim	33	2.0	2.0
Eltrombopag Olamine	7	1.8	1.8
Conjugated Estrogens And Medroxyprogesterone Acetate	7	1.8	1.8
Methoxy Polyethylene Glycol-Epoetin Beta	3	1.6	1.6
Lenalidomide	113	1.6	1.6
Exenatide	13	1.5	1.5
Tapentadol Hydrochloride	8	1.4	1.4
Etonogestrel	10	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.